Plasminogen activator inhibitor-1, free fatty acids, and insulin resistance in patients with myocardial infarction

Diabetes, Metabolic Syndrome and Obesity

Volumn 6, Issue , 2013, Pages 293-301

  Gruzdeva, Olga ^a   Uchasova, Evgenya ^a   Dyleva, Yulia ^a   Belik, Ekaterina ^a   Shurygina, Ekaterina ^a   Barbarash, Olga ^a  

^a RESEARCH INSTITUTE FOR COMPLEX ISSUES OF CARDIOVASCULAR DISEASES   (Russian Federation)

Author keywords

Free fatty acids; Insulin resistance; Myocardial infarction; Plasminogen activator inhibitor 1; Type 2 diabetes mellitus

Indexed keywords

C PEPTIDE; FATTY ACID; GLUCOSE; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; CARBOHYDRATE INTAKE; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULINEMIA; MAJOR CLINICAL STUDY; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL;

EID: 84881656917     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S46627     Document Type: Article

References (15)

1. Collet JP, Montalescot G, Vicaut E, etal. Acute release of plasminogen activator inhibitor-1in ST-segment elevation myocardial infarction predicts mortality. Circulation. 2003;108(4):391-394.
2. Ishihara M, Kojima S, Sakamoto T, etal; Japanese Acute Coronary Syndrome Study Investigators. Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era. Am Heart J. 2005;150(4):814-820.
3. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol. 2006;26(10): 2200-2207.
4. López-Alemany R, Redondo JM, Nagamine Y, Muñoz-Cánoves P. Plasminogen activator inhibitor type-1inhibits insulin signaling by competing with alphavbeta3integrin for vitronectin binding. Eur J Biochem. 2003;270(5):814-821.
5. Juhan-Vague I, Morange PE, Frere C, etal; HIFMECH Study Group. The plasminogen activator inhibitor-1-675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study. J Thromb Haemost. 2003;1(11):2322-2329.
6. Cefalu WT. Insulin resistance: cellular and clinical concepts. Exp Biol Med (Maywood). 2001;226(1):13-26.
7. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73-78.
8. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol. 2007;47(1):142-156.
9. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90(1):207-258.
10. Oliver MF. Sudden cardiac death: the lost fatty acid hypothesis. QJM. 2006;99(10):701-709.
11. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85(3): 1093-1129.
12. Kryzhanovsky VA. Diagnosis and treatment of myocardial infarction. K: Phoenix; 2001.
13. Campbell IW. Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? Drugs. 2000;60(5):1017-1028.
14. Liang X, Kanjanabuch T, Mao SL, etal. Plasminogen activator inhibitor-1modulates adipocyte differentiation. Am J Physiol Endocrinol Metab. 2006;290(1):E103-E113.
15. Katz A, Nambi SS, Mather K, etal. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7):2402-2410.